Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewML 311 is an inhibits Mcl1-BIM interaction. Inhibits viability of Mcl1-dependent tumor cell lines. Induces cell death and decreased spheroid formation in Her2 positive breast cancer cells.
M. Wt | 415.45 |
Formula | C23H24F3N3O |
Storage | Store at -20°C |
Purity | ≥99% (HPLC) |
CAS Number | 315698-17-0 |
PubChem ID | 3384730 |
InChI Key | NGAPBLRRJSKIRT-UHFFFAOYSA-N |
Smiles | CCN(CC1)CCN1C(C2=CC=C(C(F)(F)F)C=C2)C3=C(O)C4=NC=CC=C4C=C3 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
References are publications that support the biological activity of the product.
Bashari et al (2016) Mcl-1 confers protection of Her2-positive breast cancer cells to hypoxia: therapeutic implications. Breast Cancer Res. 18 26 PMID: 26921175
Bannister et al (2012) ML311: A small molecule that potently and selectively disrupts the protein-protein interaction of Mcl-1 and Bim: a probe for studying lymphoid tumorigenesis. Probe Reports from the NIH Molecular Libraries Program PMID: 23762927
Keywords: ML 311, ML 311 supplier, ML311, myeloid, cell, leukemia, 1, mcl1, BIM, inhibitors, inhibits, interaction, Bcl-2, Family, 5733, Tocris Bioscience
Citations are publications that use Tocris products.
Currently there are no citations for ML 311.
There are currently no reviews for this product. Be the first to review ML 311 and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.
There are two currently recognized forms of programmed cell death: apoptosis and necroptosis. This poster summarizes the signaling pathways involved in apoptosis, necroptosis and cell survival following death receptor activation, and highlights the influence of the molecular switch, cFLIP, on cell fate.